Moderna Inc. ($MRNA) Stock Forecast: Down 5.1% Today

What is Moderna Inc.?

Moderna, Inc. (MRNA) is a biotechnology company known for its innovative mRNA technology, particularly in vaccine development. Today, the stock experienced a strong bearish movement in the market.

Why is Moderna Inc. going down?

MRNA stock is down 5.1% on May 19, 2026 19:40

• Moderna's bearish movement today may be linked to an insider sale by President Stephen Hoge, potentially unsettling investors and adding to stock volatility.
• The market sentiment around mRNA technology and the company's need to stabilize revenue post-pandemic could be contributing to the downward trend, despite positive growth from international partnerships and new vaccines.
• Investors may also be reacting to potential legal risks from intellectual property disputes, as mentioned in a recent conference audio transcript, which might be impacting Moderna's stock performance.
• The company's strong clinical and regulatory progress, beneficial for its long-term prospects, may not be sufficient to counter the immediate market factors influencing today's bearish movement.

MRNA Price Chart

MRNA Technical Analysis

MRNA News

MRNA: International partnerships and new vaccines fuel growth amid strong clinical and regulatory progress

Moderna, Inc. (MRNA) is experiencing growth fueled by cost reductions, robust international partnerships, and new vaccine launches, particularly in oncology, supported by strong clinical data. The company is advancing regulatory approvals in the U.S. and Europe, and potential legal risks from intellectual property disputes are not expected to affect cash reserves. This assessment is based on an AI-generated summary of Moderna's RBC Capital Markets Global Healthcare Conference 2026 Audio Transcript.

https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:3348080:0-mrna-international-partnerships-and-new-vaccines-fuel-growth-amid-strong-clinical-and-regulatory-progress/

Profund Advisors LLC Increases Position in Amgen Inc. $AMGN

Profund Advisors LLC increased its stake in Amgen Inc. by 11% in the fourth quarter, bringing its total holdings to 62,287 shares valued at $20.4 million. This move follows Amgen's better-than-expected first-quarter results, with reported EPS of $5.15 and revenue of $8.62 billion, a 5.8% increase year-over-year. The company also announced a quarterly dividend of $2.52 per share, leading to an annualized yield of 3.1%, while analysts maintain a consensus "Hold" rating with an average price target of $356.15.

https://www.marketbeat.com/instant-alerts/filing-profund-advisors-llc-increases-position-in-amgen-inc-amgn-2026-05-19/

CRISPR Therapeutics stock (CH0334081137): gene-editing pioneer ahead of next earnings test

CRISPR Therapeutics, a gene-editing pioneer, is gearing up for its next earnings report with investors keenly watching its progress in gene-editing therapies and U.S. regulatory milestones. The company's business model relies heavily on collaborations and a robust pipeline focused on severe diseases like sickle cell, with future revenue potential tied to regulatory approvals and successful commercialization. Despite ongoing net losses due to significant R&D investment, the company's long-term value for U.S. investors lies in its ability to navigate complex regulatory landscapes and successfully bring its innovative CRISPR/Cas9-based treatments to market.

https://www.ad-hoc-news.de/boerse/news/ueberblick/crispr-therapeutics-stock-ch0334081137-gene-editing-pioneer-ahead-of/69370544

Moderna stock (US60770K1034): Insider sale adds to a volatile setup

Moderna President Stephen Hoge sold 53,336 shares on May 15 under a Rule 10b5-1 plan, contributing to the stock's volatile trading range. This insider sale provides a new data point for investors following the vaccine maker, whose shares are largely influenced by vaccine demand, pipeline execution, and market sentiment around mRNA technology. The company's future growth hinges on its ability to stabilize revenue post-pandemic and expand beyond its core respiratory vaccine franchise.

https://www.ad-hoc-news.de/boerse/news/ueberblick/moderna-stock-us60770k1034-insider-sale-adds-to-a-volatile-setup/69370321

WVE-006 AATD trial shows strong biomarker gains for Wave Life Sciences (WVE)

Wave Life Sciences (WVE) announced positive updated data from its RestorAATion-2 Phase 1b/2a trial of WVE-006 for alpha-1 antitrypsin deficiency (AATD). The subcutaneous RNA editing therapy demonstrated significant reductions in harmful Z-AAT protein and restoration of protective M-AAT to levels observed in low-risk MZ individuals, alongside a favorable safety profile. The company anticipates FDA feedback on an accelerated approval pathway by mid-2026.

https://www.stocktitan.net/sec-filings/WVE/8-k-wave-life-sciences-ltd-reports-material-event-8681fb702706.html

Trending Today

Silver ($XAG) Commodity Forecast: Down 5.1% Today

SL Green Realty Corp ($SLG) Stock Forecast: Down 5.3% Today

Torchmark Corporation ($GL) Stock Forecast: Down 4.0% Today

Xerox Corporation ($XRX) Stock Forecast: Down 5.2% Today

Akamai Technologies Inc. ($AKAM) Stock Forecast: Down 5.6% Today

Enphase Energy Inc. ($ENPH) Stock Forecast: Down 5.5% Today

Moderna Inc. ($MRNA) Stock Forecast: Down 5.1% Today

Edison International ($EIX) Stock Forecast: Up 7.1% Today

Pacific Gas & Electric Co. ($PCG) Stock Forecast: Up 5.5% Today

Zebra Technologies Corporation ($ZBRA) Stock Forecast: Down 5.5% Today

Moderna Inc. Price History

12.04.2026 - MRNA Stock was down 6.7%

• Moderna (MRNA) faced a downturn today, potentially influenced by profit-taking following recent positive developments.
• The dip in Merck's stock value, attributed to a one-time charge stemming from an acquisition and a setback in its pipeline, may have impacted overall sentiments towards biotech equities, including Moderna.
• Investor attention could have shifted towards companies like Halozyme Therapeutics (HALO) with optimistic revenue projections, prompting a brief sell-off in Moderna shares.
• Market influencers within the biotech domain embracing cutting-edge technologies such as AI might have diverted focus away from Moderna, contributing to its bearish performance today.

08.04.2026 - MRNA Stock was up 12.8%

• Following the release of positive Phase 3 flu vaccine data, Moderna's stock showed a strong bullish trend. The data highlighted the efficacy of mRNA-1010 compared to standard flu vaccines in older adults.
• Moderna's stock rebounded after favorable earnings and a successful performance in 2026. This reflected investor confidence in the company's mRNA platform and its potential for revenue growth beyond the realm of COVID-19 vaccines.
• The positive Phase 1 data announcement for Moderna's mRNA hantavirus vaccine further boosted investor confidence. This demonstrated how Moderna's mRNA technology can effectively target different viral diseases.
• Moderna's recent bullish market movement can be linked to its successful vaccine developments, robust earnings, and the confirmation of its mRNA platform's potential to address a broad array of health issues.

08.04.2026 - MRNA Stock was up 6.2%

• The strong bullish movement of Moderna's stock today is due to the positive Phase 1 data release for its mRNA hantavirus vaccine, showcasing its versatility in targeting different viral diseases and renewing investor confidence in the company's mRNA pipeline.
• Moderna's shares rebounded following positive quarterly earnings and a strong 2026 performance, with investors considering the transition from pandemic-driven revenues to a broader product portfolio.
• Investor sentiment received a boost as Gateway Investment Advisers LLC significantly increased its stake in Moderna, especially with promising Phase 3 results for the company's seasonal flu vaccine, mRNA-1010.
• Market sentiment towards Moderna was positive despite developments from other biotech companies like CytomX Therapeutics and Arrowhead Pharmaceuticals, underscoring the market's focus on specific companies' developments and performance.

08.04.2026 - MRNA Stock was up 13.7%

• Moderna's bullish movement can be attributed to the positive Phase 3 flu vaccine data for its mRNA-1010 candidate, showcasing superior efficacy compared to standard flu vaccines.
• The SEC filing indicating a proposed sale of securities might have initially caused some uncertainty but was overshadowed by the promising vaccine results.
• The positive news from Regeneron Pharmaceuticals receiving FDA approval for the first neurosensory gene therapy could have boosted overall investor sentiment in the biotech sector, benefiting Moderna as well.
• Moderna's potential for building durable revenue beyond COVID-19 vaccines with upcoming FDA approvals could have further fueled investor optimism, driving the stock's bullish momentum.

08.04.2026 - MRNA Stock was up 11.8%

• Ongoing research into hantavirus vaccines by Moderna may have boosted investor confidence in the company's ability to address emerging infectious diseases, contributing to the bullish movement.
• A SEC filing indicating a proposed sale of securities by Moderna may have initially caused some uncertainty among investors, but the overall positive sentiment surrounding the company's vaccine development efforts likely overshadowed this news.
• The broader positive sentiment in the biotechnology sector, as evidenced by Cboe Global Markets hitting an all-time high, could have also positively influenced Moderna's stock performance today.
• Moderna's focus on advancing its vaccine pipeline, as seen in the update on its RSV and H5 flu vaccine trial, may have further reinforced investor optimism in the company's long-term growth prospects, contributing to the bullish market movement.

11.04.2026 - MRNA Stock was down 7.7%

• Despite a 6% surge earlier, Moderna's stock faced a bearish movement, potentially influenced by profit-taking following recent positive momentum.
• Initially boosted by renewed interest in Moderna's Hantavirus vaccine due to an outbreak, concerns about normalizing COVID-era revenue and GAAP losses may have contributed to the downturn.
• Investors seem to exercise caution due to uncertainties surrounding the revenue potential of the broader mRNA platform and the company's ability to sustain competitiveness against peers like Pfizer and Novavax in the vaccine sector.
• While the market sentiment towards Moderna remains positive, driven by upcoming Phase 3 readouts and a diverse pipeline, short-term volatility could linger as investors navigate challenges tied to the pandemic.

11.04.2026 - MRNA Stock was down 5.1%

• Moderna's stock increased by 6% today, surpassing other vaccine companies like Pfizer and Novavax. This was driven by heightened interest in its Hantavirus vaccine after a recent outbreak on a cruise ship and robust Q1 2026 revenue results. However, concerns about returning to pre-COVID revenue levels and ongoing losses might have led to profit-taking and a bearish trend in the stock.
• Moderna's wide-ranging mRNA platform, along with upcoming Phase 3 study outcomes, continues to support its positive market momentum despite the recent decline.
• The overall market sentiment towards biotech companies and uncertainties about future revenue sustainability post-COVID may have played a role in today's downward movement for Moderna's stock.
• Investors are likely approaching Moderna's stock with caution due to uncertainties surrounding its revenue sources and future profitability.

13.04.2026 - MRNA Stock was down 5.4%

• Moderna's stock experienced a bearish movement despite being ranked #1 on a list of Most Impactful Companies, showcasing its significant contributions to mRNA technology and public health.
• The company's Q1 earnings report with an EPS of ($3.40) may have contributed to the drop in share price, signaling potential investor concerns about profitability.
• Investors viewing Moderna as a pandemic hedge amidst reduced demand for Covid vaccines and regulatory challenges might have led to conflicting sentiments and added to the stock's volatility.
• The overall market sentiment towards biotech companies and vaccine manufacturers could have influenced Moderna's stock movement, with investors closely monitoring developments in the healthcare sector.

13.04.2026 - MRNA Stock was down 5.4%

• Moderna observed a downward trend in its stock price today despite investor confidence in its pandemic-related value. Possible reasons for this decline include:
• Decreased demand for Covid vaccines and regulatory challenges impacting investor optimism.
• Moderna faces uncertainties regarding its future trajectory and the viability of potential trading strategies related to the "hantavirus."
• News of Dominari Holdings' strong Q1 revenue growth and Sinovac Foundation's vaccine donations might have shifted investor focus away from Moderna, affecting its stock performance.
• Denison Mines' underwhelming earnings results and a poor financial health rating from InvestingPro could have contributed to negative overall market sentiment in the healthcare and biotech sectors, influencing Moderna's stock performance.

13.04.2026 - MRNA Stock was down 5.4%

• The stock of Moderna faced a downturn despite being acknowledged as a highly impactful company globally.
• Factors such as declining demand for COVID vaccines and a complex regulatory environment may have influenced the market's pessimistic view.
• Investors appear wary of Moderna's future trajectory, particularly as the company navigates critical decisions and places bets on a "hantavirus trade" to regain momentum.
• While Moderna has received acclaim for its mRNA technology innovations, current market sentiment seems more concerned with the company's present obstacles and uncertainties.

19.04.2026 - MRNA Stock was down 5.1%

• Moderna's bearish movement today may be linked to an insider sale by President Stephen Hoge, potentially unsettling investors and adding to stock volatility.
• The market sentiment around mRNA technology and the company's need to stabilize revenue post-pandemic could be contributing to the downward trend, despite positive growth from international partnerships and new vaccines.
• Investors may also be reacting to potential legal risks from intellectual property disputes, as mentioned in a recent conference audio transcript, which might be impacting Moderna's stock performance.
• The company's strong clinical and regulatory progress, beneficial for its long-term prospects, may not be sufficient to counter the immediate market factors influencing today's bearish movement.

19.04.2026 - MRNA Stock was down 6.9%

• Moderna's stock faced a downward trend subsequent to an insider selling 53,336 shares, conducted by President Stephen Hoge. This transaction heightened stock volatility, indicating investor sensitivity to internal activities.
• The market's adverse response to the insider sale potentially reflects uncertainties about Moderna's future growth trajectory and stability post-pandemic.
• Investor focus remains on Moderna's vaccine demand, progress in pipeline projects, and endeavors to stabilize revenue, all pivotal in determining stock performance.
• Noteworthy advancements from Wave Life Sciences regarding its AATD trial possibly impacted the biotech sector positively, while Moderna's descent was influenced by the insider transaction.